Verastem, Inc. (VSTM): Price and Financial Metrics


Verastem, Inc. (VSTM)

Today's Latest Price: $1.27 USD

0.06 (4.96%)

Updated Sep 25 4:00pm

Add VSTM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

VSTM Stock Summary

  • With a price/sales ratio of 9.78, Verastem Inc has a higher such ratio than 86.69% of stocks in our set.
  • With a year-over-year growth in debt of -56.76%, Verastem Inc's debt growth rate surpasses only 4.72% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VSTM comes in at -43.64% -- higher than that of just 10.2% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Verastem Inc are VREX, CEMI, XERS, SENS, and VJET.
  • Visit VSTM's SEC page to see the company's official filings. To visit the company's web site, go to www.verastem.com.
VSTM Daily Price Range
VSTM 52-Week Price Range

VSTM Stock Price Chart Technical Analysis Charts


VSTM Price/Volume Stats

Current price $1.27 52-week high $4.67
Prev. close $1.21 52-week low $0.83
Day low $1.18 Volume 1,582,633
Day high $1.28 Avg. volume 5,034,887
50-day MA $1.36 Dividend yield N/A
200-day MA $1.86 Market Cap 215.31M

Verastem, Inc. (VSTM) Company Bio


Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.


VSTM Latest News Stream


Event/Time News Detail
Loading, please wait...

VSTM Latest Social Stream


Loading social stream, please wait...

View Full VSTM Social Stream

Latest VSTM News From Around the Web

Below are the latest news stories about Verastem Inc that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

How Many Verastem, Inc. (NASDAQ:VSTM) Shares Do Institutions Own?

Every investor in Verastem, Inc. (NASDAQ:VSTM) should be aware of the most powerful shareholder groups. Large...

Yahoo | September 18, 2020

Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that management will host an investor conference call to discuss the updated clinical data from the low-grade serous ovarian cancer (LGSOC) cohort of the ongoing investigator-initiated Phase 1/2 FRAME study. The ongoing study is evaluating VS-6766, Verastem’s RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor.

Yahoo | September 14, 2020

The Play On Verastem

"The books that the world calls immoral are books that show the world its own shame.” ― Oscar Wilde, The Picture of Dorian Gray Today, we revisit Verastem (VSTM), a small oncology outfit that comes up in comments from time to time. In early August, the company announced it has...

Bret Jensen on Seeking Alpha | September 13, 2020

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that management will present virtually at the following upcoming investor conferences:

Yahoo | September 10, 2020

Verastem sells Copiktra rights for up to $311M

Following through on its previously announced decision to sharpen its strategic focus on RAF/MEK inhibitor VS-6766 and it FAK inhibitor program in KRAS mutation-positive solid tumors, Verastem (VSTM) has sold global development and commercialization rights to Copiktra (duvelisib) to Las Vegas, NV-based Secura Bio.Under the terms of the deal, Veratem...

Seeking Alpha | August 10, 2020

Read More 'VSTM' Stories Here

VSTM Price Returns

1-mo -3.79%
3-mo -25.29%
6-mo -51.89%
1-year 0.79%
3-year -72.86%
5-year -27.43%
YTD -5.22%
2019 -60.12%
2018 9.45%
2017 174.11%
2016 -39.78%
2015 -79.65%

Continue Researching VSTM

Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:

Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7549 seconds.